Message #23 From:
NewsBot Date: January 17, 2007 06:04:00 AM
ISRY News IsoRay Medical Significantly Increases Site Licensing Pipeline of Cesium-131 from First to Second Fiscal Quarter 2007
RICHLAND, Wash.--(BUSINESS WIRE)--Spurred by broadening medical center acceptance of Cesium-131 as a
brachytherapy treatment for prostate cancer, IsoRay Medical, Inc., from
fiscal 1st Quarter 2007 to 2nd
Quarter 2007, has significantly increased the number of sites that are
either revenue producing, in the process of getting licensed for
Cesium-131, or are targeted and are in advanced discussions to adopt
Cesium-131.
IsoRay, Inc. ("IsoRay") (OTCBB:ISRY) is a medical isotope company that
focuses on brachytherapy solutions for prostate and other malignant
tissue cancers through use of its proprietary Cesium-131 radioisotope.
Over the last two-quarters, the number of medical centers, hospitals and
clinics in the site licensing pipeline jumped from 45 to 91 sites.
Revenue producing sites have jumped from 17 to 29. Sites in the process
of amending their licenses doubled from 6 to 12, and sites that are in
late stage discussions to adopt Cesium-131 have grown from 22 to 50.
(See chart below.)
“The marked increase in the number of licensed
and ordering locations has created significant momentum. These are
important locations to us. They were among the first to adopt and
embrace Cesium-131 as a treatment option and we are seeing their
influence broaden to other centers,” said
IsoRay Chairman and CEO Roger Girard.
Girard cited the outstanding results from those currently using Cs-131
and the expansion of IsoRay’s sales team as
key factors in the continued site adoption and sales growth. The number
of sales personnel increased from 3 to 10 during the last quarter.
“These are seasoned industry veterans and
their efforts have generated almost immediate results. We emphasize
providing superior training, education and support for our customers,
and the sales team’s efforts are having a
positive impact on progressive conversions beginning with the licensing
process.”
Licensing of Cs-131
Q1’07
Q2’07
Licensed & Ordering
17
29
License in Process
6
12
Pre-licensing Process
22
50
Total Pipeline
45
91
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole
producer of the Cesium-131 brachytherapy seed, used to treat prostate
and other cancers. The Cesium-131 seed offers a significantly shorter
half-life than the two other isotopes commonly used for brachytherapy,
which results in a substantially faster delivery of therapeutic
radiation and lower probability of cancer cell survival. IsoRay is based
in Richland, Washington. More information is available about IsoRay at www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay’s
future expectations, including: the advantages of our Cesium-131 seed,
future increases in the number of centers licensed to order Cesium-131,
retention and continued growth of our sales team, the level of market
share our seed may attain, and all other statements in this release,
other than historical facts, are forward-looking statements. It is
important to note that actual results and ultimate corporate actions
could differ materially from those in such forward-looking statements
based on such factors as physician acceptance, training and use of our
products, our ability to successfully manufacture, market and sell our
products, our ability to manufacture our products in sufficient
quantities to meet demand within required delivery time periods while
meeting our quality control standards, and our ability to enforce our
intellectual property rights, and other risks detailed from time to time
in IsoRay's reports filed with the SEC.
